MMA Asset Management’s Royalty Pharma RPRX Stock Holding History

MMA Asset Management’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$695K	Sell	12,398 -1,132	-8%	-$58.9K	0.22%	90
2026 Q1	$649K	Sell	13,530 -152	-1%	-$6.66K	0.23%	83
2025 Q4	$529K	Sell	13,682 -127	-0.9%	-$4.84K	0.19%	100
2025 Q3	$487K	Buy	13,809 +4,960	+56%	+$180K	0.16%	111
2025 Q2	$319K	Buy	+8,849	New	+$293K	0.12%	127

Other funds holding RPRX

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MMA Asset Management's RPRX Position: Q2 2026 in Review

MMA Asset Management reduced its Royalty Pharma (RPRX) stake by 8.4% in Q2 2026, selling an estimated $58.9K and leaving 12,398 shares worth $695K. The position accounts for 0.22% of the portfolio, ranked #90.

MMA Asset Management first reported a position in RPRX in Q2 2025 and has held it in 5 quarters since. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

MMA Asset Management held 12,398 shares of Royalty Pharma worth $695K as of Q2 2026.
MMA Asset Management sold 1,132 Royalty Pharma shares in Q2 2026, an estimated $58.9K.
Royalty Pharma made up 0.22% of MMA Asset Management's portfolio in Q2 2026, its #90 holding.
MMA Asset Management first reported a position in Royalty Pharma in Q2 2025 and has held it in 5 quarters since.
645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on MMA Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.